HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
XGN
Exagen Inc.
XGN lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
XGN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
XGN's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
XGN PE Valuation
XGN has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
XGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
XGN has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
XGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.76 | +$0.16 |
| Q2 2026 | -$0.82 | +$0.07 |
| Q1 2026 | -$0.90 | -$0.06 |
| Q4 2025 | -$0.93 | -$0.10 |
| Q3 2025 | -$0.92 | +$0.02 |
| Q2 2025 | -$0.89 | +$0.08 |
| Q1 2025 | -$0.84 | +$0.25 |
| Q4 2024 | -$0.83 | +$0.51 |
XGN has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over XGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over XGN on profitability, with a higher operating margin.
XGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.4M | +6.8% |
| Q2 2026 | $19.9M | +16% |
| Q1 2026 | $17.3M | +12% |
| Q4 2025 | $16.6M | +22% |
| Q3 2025 | $17.2M | +38% |
| Q2 2025 | $17.2M | +14% |
| Q1 2025 | $15.5M | +7.5% |
| Q4 2024 | $13.7M | -0.8% |
XGN's revenue has grown year over year for seven quarters in a row: $18M last quarter, up 6.8% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -24% | -5.9 points |
| Q2 2026 | -8.6% | +6.6 points |
| Q1 2026 | -20% | +2 points |
| Q4 2025 | -30% | -5.1 points |
| Q3 2025 | -18% | +19 points |
| Q2 2025 | -15% | +1.9 points |
| Q1 2025 | -22% | -0.9 points |
| Q4 2024 | -25% | +13 points |
XGN's operating margin was −24% last quarter, down 5.9 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over XGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
XGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.8M | -204% |
| Q2 2026 | $3.4M | +$6.5M |
| Q1 2026 | -$10.6M | +$139K |
| Q4 2025 | -$3.1M | -1509% |
| Q3 2025 | $2.7M | +$5M |
| Q2 2025 | -$3.1M | -$532K |
| Q1 2025 | -$10.8M | -$1.7M |
| Q4 2024 | $217K | -97% |
XGN has burned cash in almost every quarter: −$13M over the past year, against −$11M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over XGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
XGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.8% | +685K shares |
| 1 year | +8.3% | +1.9M shares |
| 3 years | +40% | +7.2M shares |
| 5 years | +47% | +7.9M shares |
| Available history | +97% | +12.3M shares |
XGN has 25M diluted shares, up 8.3% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
XGN Net Leverage
XGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
XGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.3 | Neutral |
| Stochastic | 38.4 | Neutral |
XGN's weekly RSI is 40 (neutral) and its Stochastic is 38 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
XGN PE vs Healthcare Sector
XGN has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
XGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.39 | 40% below |
| 20 week MA | $6.68 | 34% below |
| 50 week MA | $5.21 | 15% below |
| 100 week MA | $6.05 | 27% below |
| 200 week MA | $4.23 | 4.3% above |
XGN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
XGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25.7 | $12.3 | -52% |
| 2021 | $12.3 | $11.0 | -10% |
| 2022 | $11.0 | $2.45 | -78% |
| 2023 | $2.45 | $1.99 | -19% |
| 2024 | $1.99 | $4.71 | +137% |
| 2025 | $4.71 | $6.13 | +30% |
| 2026 YTD | $6.13 | $4.41 | -28% |
XGN has the edge over HIMS on returns for 2026, with the stronger performance.